IIBBA   05544
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE BUENOS AIRES
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Oncoprotein based immunotherapy for HPV-linked cervical cancer
Autor/es:
CERUTTI, M.L
Lugar:
Ciudad de buenos Aires
Reunión:
Conferencia; FAIC2010. First French-Argentine Immunology Congress; 2010
Institución organizadora:
Sociedad Argentina de Inmunología
Resumen:
High-risk human papillomaviruses
(HPV) are the main etiological agent of cervical cancer, the leading cause of cancer death
among women in low-income countries. Furthermore, they are also highly associated with the development of others anogenital and oropharyngeal carcinomas. Commercially available prophylactic HPV
vaccines were shown to be ineffective on pre-existing neoplastic processes,
thus having no immediate impact on the actual incidence of HPV-related cancers.
HPV E7 and E6 early oncoproteins represent ideals targets for immunotherapeutic
intervention due to their key role in cellular
transformation and constitutive
expression in HPV-associated tumors. Recently,
we have developed a recombinant E7-based vaccine, exhibiting strong immunotherapeutic
properties in a well established HPV-16 tumour model. Vaccination
of female mice with low doses of the recombinant HPV-16 E7vaccine totally prevented
tumour outgrowth, even after a 3 months re-challenge. Therapeutic treatment of tumour-bearing mice
with the vaccine-type molecule also shows a remarkable activity, completely reverting
the tumor growth. Preliminary in vitro
experiments demonstrate that the in vivo therapeutic effect of our E7-based
vaccine is due to the induction of a long lasting CD8+ T-cell
response. These proof-of-principle
experiments demonstrate the potential applicability of our vaccine candidate to
the treatment of HPV-related neoplastic lesions.